Futura Medical Regulatory News (FUM)

9 Aug 2007 07:01

Futura Medical PLC09 August 2007 For immediate release 9 August 2007 Futura Medical Plc ("Futura" or "the Company") Successful results from CSD500 condom study Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovativeproducts for the consumer healthcare market, is pleased to announce positiveresults from a user study of CSD500, Futura's novel product to help men maintaina full erection when wearing a condom. The study, equally funded by Futura andits marketing and distribution partner SSL International plc (SSL), successfullymet its primary endpoint of demonstrating a firmer erection through the use ofthe CSD500 condom compared with a standard condom. This result was highlystatistically significant. The study's secondary endpoints of increased penile size and a longer-lastingsexual experience also revealed positive, statistically significant data. Theseresults from the double-blind, randomised, cross-over study will complete theregulatory package for CSD500. The study included 108 healthy couples, the men of which had at some timeexperienced a loss or partial loss of erection whilst using standard condoms. Agood safety and tolerability profile was reported for CSD500. James Barder, Futura's Chief Executive, said: "I am delighted by these highlystatistically significant study results, which give us confidence that theCSD500 product will gain marketing approval and, once launched, be a commercialsuccess. We look forward to continuing to work closely with SSL." For any further information please contact: Futura Medical plcJames Barder, Chief Executive Tel: +44 (0) 1483 685 670mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Canaccord Adams Tel: +44 (0) 20 7050 6500Mark Ashurst For any media enquiries please contact:Buchanan Communications Tel: +44 (0) 020 7466 5000Mark Court / Rebecca Dietrich Notes Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products forconsumer healthcare. The Company is developing a portfolio of products and itsstrategy is to license their manufacture and distribution to majorpharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market ofthe London Stock Exchange. The information pursuant to AIM rule 26 is now available at Futura's website:www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange